16598749

Source:http://linkedlifedata.com/resource/pubmed/id/16598749

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0008976, umls-concept:C0019932, umls-concept:C0039286, umls-concept:C0043210, umls-concept:C0232970, umls-concept:C0290883, umls-concept:C0445204, umls-concept:C0600558, umls-concept:C0878174, umls-concept:C1707455
pubmed:issue	10
pubmed:dateCreated	2006-5-3
pubmed:abstractText	The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0-2, M0), or potentially operable (T4b, N0-2, M0) breast cancer. The effect of preoperative endocrine therapy in patients scheduled for mastectomy or with inoperable tumors at baseline was also investigated.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Nitriles, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen, http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen, http://linkedlifedata.com/resource/pubmed/chemical/Triazoles, http://linkedlifedata.com/resource/pubmed/chemical/anastrozole
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0008-543X
pubmed:author	pubmed-author:BinesJoseJ, pubmed-author:BuzdarAman UAU, pubmed-author:CataliottiLuigiL, pubmed-author:DubePierreP, pubmed-author:NoguchiShinzaburoS, pubmed-author:PetrakovaKatarinaK, pubmed-author:TakatsukaYuichiY, pubmed-author:de OliveiraCelia ToselloCT
pubmed:copyrightInfo	Copyright 2006 American Cancer Society
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	106
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2095-103
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:16598749-Aged, pubmed-meshheading:16598749-Breast Neoplasms, pubmed-meshheading:16598749-Confidence Intervals, pubmed-meshheading:16598749-Cross-Sectional Studies, pubmed-meshheading:16598749-Dose-Response Relationship, Drug, pubmed-meshheading:16598749-Double-Blind Method, pubmed-meshheading:16598749-Drug Administration Schedule, pubmed-meshheading:16598749-Female, pubmed-meshheading:16598749-Follow-Up Studies, pubmed-meshheading:16598749-Humans, pubmed-meshheading:16598749-Logistic Models, pubmed-meshheading:16598749-Mastectomy, pubmed-meshheading:16598749-Middle Aged, pubmed-meshheading:16598749-Neoplasm Staging, pubmed-meshheading:16598749-Neoplasms, Hormone-Dependent, pubmed-meshheading:16598749-Nitriles, pubmed-meshheading:16598749-Odds Ratio, pubmed-meshheading:16598749-Postmenopause, pubmed-meshheading:16598749-Preoperative Care, pubmed-meshheading:16598749-Receptors, Estrogen, pubmed-meshheading:16598749-Reference Values, pubmed-meshheading:16598749-Risk Assessment, pubmed-meshheading:16598749-Survival Analysis, pubmed-meshheading:16598749-Tamoxifen, pubmed-meshheading:16598749-Treatment Outcome, pubmed-meshheading:16598749-Triazoles
pubmed:year	2006
pubmed:articleTitle	Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
pubmed:affiliation	Clinica Chirurgica 1, University degli Studi di Firenze, Firenze, Italy.
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study